A Double-Blind, Randomized, Placebo-Controlled Exploratory Study to Assess the Efficacy and Safety of TC-5214 in the Treatment of Subjects With Moderate to Severe Palmar Hyperhidrosis
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 60
- Locations
- 3
- Primary Endpoint
- HDSS Success
Study Overview
Brief Summary
This is a pilot exploratory study to evaluate the safety and efficacy of TC-5214 in subjects with palmar hyperhidrosis.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description
The study drug will be provided as oral tablets with active and placebo indistinguishable in product and packing characteristics.
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subject has a clinical diagnosis of primary hyperhidrosis of the palms
- •Subject is currently drug-naïve for hyperhidrosis medications
- •Females must be post-menopausal, surgically sterile, or use an effective method of birth control.
Exclusion Criteria
- •Subject is pregnant, lactating, is planning to become pregnant during the study, or is less than one year postpartum.
- •Subject is a smoker within one year prior to Visit 1/Screening.
- •Subject has known history of secondary hyperhidrosis.
- •Subject has existence of neurological, psychiatric, endocrine, or other disease that can cause secondary hyperhidrosis or affect sweating.
- •Subject has known history of Sjögren's syndrome or Sicca syndrome.
- •Subject has used any of the following hyperhidrosis medications or therapies within the specified timeframe:
- •Iontophoresis to the palms within four weeks prior to baseline visit;
- •Botulinum toxin to the palms within one year prior to baseline visit;
- •Prior surgical procedures to the palms (e.g., sympathectomy, debulking of sweat glands);
- •Prior medical device treatment to the palms (approved or investigational);
- •Any treatments for hyperhidrosis within four weeks prior to baseline visit.
- •Subject is currently enrolled in an investigational drug or device study.
- •Subject has previously participated in a clinical study of dexmecamylamine or TC-
- •Subject has used an investigational drug or investigational device treatment within 30 days prior to baseline.
- •Subject has a history of sensitivity to any of the ingredients in the study drugs.
Arms & Interventions
High Dose (4 mg)
Oral tablet containing 2 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
Intervention: Dexmecamylamine HCl (Drug)
Low Dose (2 mg)
Oral tablet containing 1 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
Intervention: Dexmecamylamine HCl (Drug)
Placebo
Oral tablet containing no active drug. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
Intervention: Placebo (Other)
Outcomes
Primary Outcomes
HDSS Success
Time Frame: Day 14 (End of Treatment)
Proportion of subjects with at least a 1, 2, or 3 point reduction in Hyperhidrosis Disease Severity Scale (HDSS) score from Baseline
Secondary Outcomes
- Absolute change of Sweat Production(Day 14 (End of Treatment))
- Reduction in Sweat Production(Day 14 (End of Treatment))